NexImmune
Gaithersburg
About NexImmune
NexImmune is an early stage biopharmaceutical company developing novel immuno-therapeutics based on the proprietary Artificial IMmune (AIMTM) technology. The AIM technology provides an important advance in the development of immunotherapies for a variety of cancers and other diseases. The AIM technology has been designed to orchestrate specific immune system responses in a highly controllable and reproducible way independent of the healthiness or abundance of the patient’s natural antigen presenting cell (APC) population. Natural APCs are major players in the body’s immune system as they direct the immune system cells in attacks on specifically targeted antigens and cells. However, under certain disease conditions, natural APCs can be damaged, absent or inactive.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $87.4M
- Funding stage: IPO
- Last round: Post-IPO Equity (Feb 2024)
- Ticker: nasdaq:NEXI
- Website: neximmune.com
- Phone: 3018610009
Industries & Categories
Biopharma, Biotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/neximmune-47798 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.